Patents by Inventor Dominic Behan
Dominic Behan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110177612Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: September 13, 2010Publication date: July 21, 2011Inventors: David J. Unett, Ruoping Chen, Jeremy G. Richman, Daniel Connolly, Huong T. Dang, Bryan Choi, James Leonard, Yaron Hakak, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Kevin P. Lowitz
-
Patent number: 7741064Abstract: The invention provides materials and methods relating to G-protein coupled receptor (GPCR) oligomers. Complexes of two or more GPCRs associated with G-proteins are provided. Also provided are fusion proteins comprising a GPCR and a G-protein, nucleic acids, expression vectors and host cells. Methods of producing the complexes and fusion proteins of the invention are also provided.Type: GrantFiled: May 12, 2008Date of Patent: June 22, 2010Assignee: The University Court of the University of GlasgowInventors: Graeme Milligan, Dominic Behan
-
Publication number: 20080286828Abstract: The invention provides materials and methods relating to G-protein coupled receptor (GPCR) oligomers. Complexes of two or more GPCRs associated with G-proteins are provided. Also provided are fusion proteins comprising a GPCR and a G-protein, nucleic acids, expression vectors and host cells. Methods of producing the complexes and fusion proteins of the invention are also provided.Type: ApplicationFiled: May 12, 2008Publication date: November 20, 2008Inventors: Graeme Milligan, Dominic Behan
-
Patent number: 7405053Abstract: The invention provides materials and methods relating to G-protein coupled receptor (GPCR) oligomers. Complexes of two or more GPCRs associated with G-proteins are provided. Also provided are fusion proteins comprising a GPCR and a G-protein, nucleic acids, expression vectors and host cells. Methods of producing the complexes and fusion proteins of the invention are also provided.Type: GrantFiled: May 18, 2004Date of Patent: July 29, 2008Assignee: The University Court of the University of GlasgowInventors: Graeme Milligan, Dominic Behan
-
Publication number: 20080009551Abstract: The subject invention provides methods for making ligand upregulatable G-protein coupled receptors (GPCRs). Ligand upregulatable GPCRs contain a modified TM5-IC3-TM6 segment, which provides for increased levels of the ligand upregulatable GPCR in a host cell in the presence of a ligand as compared to the absence of the ligand. The subject invention also provides assays for screening test compounds for a ligand of a GPCR using a ligand upregulatable GPCR. In these assays, a ligand upregulatable GPCR is contacted with a test compound, and an increase in the detectable amount of the ligand upregulatable GPCR in the host cell indicates that the test compound is a ligand of the GPCR. Said indicated ligands encompass modulators of the GPCR. Said modulators of the GPCR are particularly useful in treating GPCR-related conditions.Type: ApplicationFiled: April 29, 2004Publication date: January 10, 2008Applicant: Arena Pharmaceuticals, Inc.Inventors: Fu-Yue Zeng, Dominic Behan
-
Publication number: 20070275410Abstract: The subject invention provides methods for detecting a GPCR-binding partner complex. In general, the methods involve co-producing two polypeptides, one of which being a GPCR, isolating one of the polypeptides using a substrate with affinity for that polypeptide, and directly detecting the presence of the other polypeptide on the substrate. In some embodiments, the affinity substrate is addressable. The two polypeptides may be the same or different GPCRs, or a GPCR and a non-GPCR polypeptide. The subject invention further provides methods for identifying whether a polypeptide is a binding partner for a GPCR. In addition, the subject invention provides methods of screening for agents that modulate the binding of a GPCR to a binding partner for that GPCR. The subject methods and compositions find use in a variety of research and therapeutic applications, particularly in methods to identify agents for treating GPCR-binding partner complex-related disorders.Type: ApplicationFiled: August 9, 2004Publication date: November 29, 2007Applicant: Arena Pharmaceuticals, Inc.Inventors: Fu-Yue Zeng, Dominic Behan
-
Publication number: 20070099263Abstract: The invention provides materials and methods relating to G-protein coupled receptor (GPCR) oligomers. Complexes of two or more GPCRs associated with G-proteins are provided. Also provided are fusion proteins comprising a GPCR and a G-protein, nucleic acids, expression vectors and host cells. Methods of producing the complexes and fusion proteins of the invention are also provided.Type: ApplicationFiled: May 18, 2004Publication date: May 3, 2007Inventors: Graeme Milligan, Dominic Behan
-
Publication number: 20070079392Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: November 22, 2006Publication date: April 5, 2007Applicant: Arena Pharmaceuticals, Inc.Inventors: Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Huong Dang, Bryan Choi, James Leonard, Yaron Hakak, Kevin Lowitz, David Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly
-
Publication number: 20070072248Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown (“orphan GPCR receptors”), and most particularly to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.Type: ApplicationFiled: November 21, 2006Publication date: March 29, 2007Applicant: Arena Pharmaceuticals, Inc.Inventors: Ruoping Chen, Chen Liaw, Kevin Lowitz, Derek Chalmers, Dominic Behan
-
Publication number: 20060240523Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor and to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.Type: ApplicationFiled: June 30, 2006Publication date: October 26, 2006Applicant: Arena Pharmaceuticals, Inc.Inventors: Chen Liaw, Derek Chalmers, Dominic Behan, Dominique Maciejewski-Lenior, James Leonard, I-Lin Lin, Daniel Ortuno
-
Publication number: 20050227295Abstract: The invention disclosed in this patent document relates to transmembrane receptors, more particularly to a human G protein-coupled receptor for which the endogenous ligand is unknown (“orphan GPCR receptors”), and most particularly to mutated (non-endogenous) versions of the human GPCRs for evidence of constitutive activity.Type: ApplicationFiled: November 26, 2003Publication date: October 13, 2005Inventors: Ruoping Chen, Chen Liaw, Kevin Lowitz, Derek Chalmers, Dominic Behan
-
Publication number: 20050154029Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: August 31, 2004Publication date: July 14, 2005Applicant: Arena Pharmaceuticals, Inc.Inventors: David Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly, Huong Dang, Bryan Choi, James Leonard, Yaron Hakak, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Kevin Lowitz
-
Publication number: 20050119182Abstract: Disclosed herein are non-endogenous, constitutively activated forms of the human 5-HT2A and human 5-HT2C receptors and uses of such receptors to screen candidate compounds. Further disclosed herein are candidate compounds identified by the screening method which act at the 5HT2A receptors. Yet further disclosed is a new class of compounds which act at the 5HT2A receptors.Type: ApplicationFiled: November 2, 2004Publication date: June 2, 2005Applicant: Arena Pharmaceuticals, Inc.Inventors: Dominic Behan, Derek Chalmers, Chen Liaw, Joseph Russo, William Thomsen
-
Publication number: 20050004178Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: July 23, 2004Publication date: January 6, 2005Applicant: Arena Pharmaceuticals, Inc.Inventors: David Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Huong Dang, Bryan Choi, James Leonard, Yaron Hakak, Kevin Lowitz
-
Publication number: 20040142377Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.Type: ApplicationFiled: December 6, 2002Publication date: July 22, 2004Applicant: Arena Pharmaceuticals, Inc.Inventors: David J. Unett, Ruoping Chen, Jeremy Richman, Daniel Connolly, Huong T. Dang, Bryan Choi, James Leonard, Yaron Hakak, Chen Liaw, Dominic Behan, Derek Chalmers, Michael Lerner, Kevin P. Lowitz